Vaccinate Influenza Vaccine For Human->aspalthic products

Join

Help

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Vaccinate Influenza Vaccine For Human

Category :

Chemicals->Chemical->aspalthic products

Product Specification

Model No:	0.5ml/Syringe

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

Product Detail

[Drug name]


Adopted name: Influenza Vaccine (Split Virion), Inactivated


[Description]


The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus.  It is a slightly milky-white liquid, containing thimerosal as a preservative. 


Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. ) 


Subsidiary materials: All the components of subsidiary materials approved shall be listed.


[Eligibles]


Suscepitable individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.


[Action and use]                           


The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.


[Specifications]


0. 25 ml or 0.5 ml per container.  0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15 μg of influenza haemagglutinin of each influenza virus strain.


[Administration and dosage]


(1) Inject i. m. in the deltoid muscle of the lateral upper arm.


(2) Inoculate before and during the epidemic season of influenza. Inject single human dose of 0.5 ml vaccine for adults and children aged above 3 years. Inject two human doses of 0.25 ml vaccine for children aged between 6 months and 3 years at intervals of 2-4 weeks.


[Adverse reactions]


Common adverse reactions


(1) Pain, tenderness, redness, swelling and itching may occur at the injection sites generally within 24 hours after vaccination, which can be relieved spontaneously within 2-3 days in most cases.                


(2) Transient fever may occur a and can be relieved spontaneously within a short period and need no particular treatment in most cases.


Rare adverse reactions


(1) Transient common cold symptoms and discomfort may occur after vaccination which can be relieved spontaneously and need no particular treatment.                


(2) Severe fever: Physical therapy and symptomatic treatment shall be adopted to prevent febrile convulsion.


Extremely rare adverse reactions


(1) Allergic rash: Urticaria may occur generally within 72 hours after vaccination, if it occurs the recipients shall go to the clinic promptly and receive anti-anaphylactic treatment.


(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination, emergency measures shall be adopted immediately including prompt injection of adrenaline.


(3) Allergic purpura: The recipients with allergic purpura shall go to t.he clinic promptly and receive anti-anaphylactic treatment with corticosteroid. If the treatment is inappropriate or delayed,  purpuric  nephritis may be complicated.



 


[Feature]


Taking the most advanced influenza producing technology, virus splitting, purification, control tests and specifications are in accordance with WHO standard.


Good vaccine quality, satisfied immunity results, ideal immnunogenicity, high seroconversion rate, anti-body increasing time, all are above the standards set by European Union.


Special advise: the vaccine should be injected annually.


1. For adult use in vial and persons aged above 3.


2. For adult use in pre-filled syringe and persons aged above 3.


3. For paediatric use in vial aged between 6 months and 35 months.


4. For paediatric use in pre-filled-syringe aged between 6 months and 35 months.


 


1.influenza vaccine                                                      


2.split virion                                                                 


3.WHO recommended strains                                   


4.against influenza virus 


 

 <img src="http://i.bosscdn.com/product/4b/7c/6b/3e1521af692db14cd8709065d6.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Influenza Vaccine-vial" alt="Influenza Vaccine-vial" /> 
 


 


 



 
ccls-vaccine.com

More Products from this Supplier

Group A and C Meningococcal Polysaccharide Vaccine

Rabies vaccine for 3 years

PFS Varicella Vaccine, Live

Clinical Meningococcal Polysaccharide Vaccine


[ Back Products Catalog ]

Commerce Member:
Please log in your ID and password, we will later fill in relating info.

ID:

Password:

Remember my ID on this computer


	Complete this form below to send out your enquiries. All enquiries will be automatically sent to the company you want to develop.

	Subject
	Content	(Don't input Company Name, E-Mail, Phone Number, Fax Number, and URL)

Company Profile:

* Company Name

*E-mail

*Country

*Contact Person

URL

*Phone

- -

Fax

- -

*Postal code

*City

*Street Address

*Business Nature

Distributor Exporter Importer Manufacturer
Whole Sale Retailer Reseller Retrofitter User
Others, please specify:

*Security Code


Enter the security code.